biostudies-literatureUnknown41(1)Amin HM<h4>Background and objective</h4>Targeting the interleukin-23 (IL-23) pathway is an emerging therapeutic strategy for moderate to severe ulcerative colitis (UC). This systematic review and meta-analysis evaluated the efficacy and safety of IL-23 inhibitors for induction and maintenance therapy in UC.<h4>Methods</h4>A systematic search of PubMed, Cochrane, and Google Scholar was conducted up to May 2025 to identify randomized controlled trials (RCTs) of IL-23 inhibitors (mirikizumab, risankizumab, guselkumab) in UC. Data were analyzed using Review Manager (RevMan 5.4) with a random-effects model.<h4>Results</h4>Seven RCTs (four induction, three maintenance) including 4203 patients were analyzed. IL-23 inhibitors significantly increased clinical remission during both induction (RR 1.52) and International journal of colorectal disease1https://www.ebi.ac.uk/biostudies/studies/S-EPMC12764650biostudies-literatureSafety and efficacy of IL-23 inhibitors in patients with moderate to severe ulcerative colitis: a systematic review and meta-analysis of randomized controlled trials.PMC12764650Hasan AGardezi SAAlbustanji QAhmed RShahzad MAhmed MAbukhater RHasan SKhalid SMMajeed SLilley RAtique AShahzad MAAmin HMSadique HShoaib MSfalseSafety and efficacy of IL-23 inhibitors in patients with moderate to severe ulcerative colitis: a systematic review and meta-analysis of randomized controlled trials.<h4>Background and objective</h4>Targeting the interleukin-23 (IL-23) pathway is an emerging therapeutic strategy for moderate to severe ulcerative colitis (UC). This systematic review and meta-analysis evaluated the efficacy and safety of IL-23 inhibitors for induction and maintenance therapy in UC.<h4>Methods</h4>A systematic search of PubMed, Cochrane, and Google Scholar was conducted up to May 2025 to identify randomized controlled trials (RCTs) of IL-23 inhibitors (mirikizumab, risankizumab, guselkumab) in UC. Data were analyzed using Review Manager (RevMan 5.4) with a random-effects model.<h4>Results</h4>Seven RCTs (four induction, three maintenance) including 4203 patients were analyzed. IL-23 inhibitors significantly increased clinical remission during both induction (RR 1.52) and 2025-01-01T00:00:00Z2025 Dec2026-06-06T10:20:49.783Z2026-05-28T03:13:06.494ZS-EPMC127646504146794310.1007/s00384-025-05014-5